Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00280267 · ClinicalTrials.gov registry record · Phase 2

Testosterone Therapy After Hip Fracture in Elderly Women

A Phase 2 study of Muscle Weakness and Hip Fracture, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
1
Study location

NCT00280267 is a Phase 2 study of Muscle Weakness and Hip Fracture that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00280267, a Phase 2 study of Muscle Weakness and Hip Fracture, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the feasibility of testosterone replacement therapy in frail elderly female hip fracture patients who have testosterone deficiency, and to obtain preliminary information about the effects of testosterone therapy on muscle strength and size, bone density, mobility, daily functioning, and quality of life.

Interventions

  • DRUG Testosterone gel

Study Locations (1)

Missouri

  • Washington University School of Medicine, Division of Geriatrics and Nutritional Science - St Louis

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2004-08
Est. Completion 2006-12
Phase Phase 2

What the Registry Record Tells You About NCT00280267

The ClinicalTrials.gov registry entry for NCT00280267 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (80% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Muscle Weakness appearing as the primary indexed condition, and to 1 intervention - of which Testosterone gel is the first listed.

NCT00280267 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT00280267 about?

NCT00280267 is a clinical study titled "Testosterone Therapy After Hip Fracture in Elderly Women". The purpose of this study is to determine the feasibility of testosterone replacement therapy in frail elderly female hip fracture patients who have testosterone deficiency, and to obtain preliminary information about the effects of testosterone therapy on muscle strength and size, bone density, mob...

What is the current status of trial NCT00280267?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2004-08. Estimated completion is 2006-12.

What conditions does trial NCT00280267 study?

This clinical trial studies the following conditions: Muscle Weakness, Hip Fracture, Testosterone Deficiency.

What interventions are being tested in trial NCT00280267?

The interventions under investigation include: Testosterone gel (DRUG).

Who is sponsoring clinical trial NCT00280267?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00280267 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Muscle Weakness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.